Endo Reports Fourth Quarter And Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Endo Reports Fourth Quarter And Full Year 2015 Financial Results
March 2, 2016 7:10 AM EST
Mizuho Securities reiterated a Neutral rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $42.00 (from $55.00), following the company's 4Q earnings report. ENDP reported revenues of $1.07B, in-line with consensus' estimate. EPS was reported at $1.36, ahead of expectations of $1.27. ENDP introduced... More
March 1, 2016 9:04 AM EST
Piper Jaffray maintained an Overweight rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $81.00 (from $83.00), following the company's relatively in-line 4Q earnings results. Endo reported 4Q15 non-GAAP EPS of $1.36 on revenues of $1.1B. Sales of Xiaflex in 4Q15 were $50M, up 26% versus 3Q15 sales of $40M, with ENDP citing... More
March 1, 2016 7:50 AM EST
Leerink Partners maintained an Outperform rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $51.00 (from $64.00), following the company's 4Q earnings report. ENDP generics were unfavorably impacted by increased pricing pressure in pain and commodity products within legacy Qualitest, an... More
February 29, 2016 6:34 AM EST
Endo Int'l (NASDAQ: ENDP) reported Q4 EPS of $1.36, $0.09 better than the analyst estimate of $1.27. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion.
GUIDANCE:
Endo Int'l sees FY2016 EPS of $5.85-$6.20, versus the consensus of... More
